Resilience Care, a digital oncology platform co-founded with Gustave Roussy Institute, has announced its expansion into the United States after establishing operations across 200 European clinical centres supporting over 35,000 patients. The company has appointed Greg Orr, former COO of Jasper Health, as General Manager for the US market. The platform addresses the "between-visit blind spot" in cancer care through real-time symptom tracking and adaptive treatment pathways. In Europe, the system has driven a four- to five-fold increase in nursing capacity whilst maintaining an 85% patient adherence rate after one year of use. Research shows the platform reduces hospitalisations by up to 38% and decreases severe treatment-related toxicities by 25%. The company has assembled a US advisory board including Eddie Martucci of Akili Interactive and former Merck oncology executive Jill DeSimone.

Resilience, a Paris-based healthtech startup, has secured €25 million in funding to expand its cancer patient monitoring solutions both domestically and internationally. The company, which operates in over 90 hospitals, aims to increase its presence in Belgium and Germany. The funding round was led by Red River West and Picus Capital, with participation from Cathay Innovation, Singular, and Seaya Ventures. Resilience's remote monitoring platform is the first oncology-related device reimbursed by France's national social security.